Your Health, We Care
Release date: 2026-01-09 16:50:00 Article From: Lucius Laos Recommended: 71
Capmatinib (brand name: Capmatinib) is an anticancer drug indicated for the treatment of metastatic non-small cell lung cancer (NSCLC). The tumors in such NSCLC patients harbor a specific mutation that causes exon 14 skipping in the MET gene encoding the membrane receptor HGFR (hepatocyte growth factor receptor).
The dosage of this medicine varies from patient to patient. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. In addition, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
For oral dosage form (tablets) in the treatment of metastatic non-small cell lung cancer:
Adults: 400 milligrams, twice a day. Your doctor may adjust the dosage based on your needs and tolerance.
Children: The dosage and administration must be determined by a doctor.
Capmatinib should be stored at room temperature, between 68°F and 77°F (20°C and 25°C). For short periods of time (e.g., during transportation), it may be exposed to temperatures ranging from 59°F to 86°F (15°C to 30°C). Store in a cool and dry place.
Keep Capmatinib in its original medication bottle. There is a small packet (desiccant) inside the bottle to help keep the medicine dry. Do not ingest the desiccant or remove it from the bottle. Discard any remaining Capmatinib tablets six weeks after opening the bottle.
The following are the most common side effects of Capmatinib. If any of these side effects bother you, inform your doctor or pharmacist.
1. Fluid retention (edema).
2. Nausea and vomiting.
3. Muscle or joint pain.
4. Fatigue and weakness.
5. Shortness of breath (dyspnea).
6. Cough.
7. Decreased appetite.
Capmatinib may cause other side effects not listed here. If you think you are experiencing any side effects from the medication, contact your doctor or pharmacist.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1622025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
